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By Joe Bick, M.D.*
Chief Medical Officer, HIV Treatment Services at
California Medical Facility in Vacaville, California
Department of Corrections.
It's late in the afternoon on Christmas
Eve, and you receive a call that a correc-
tional officer has just suffered a deep
needle stick from a syringe found during
a cell search.  Are you prepared?
Managing a successful blood borne
pathogen (BBP) exposure control pro-
gram within a correctional setting can be
very challenging. Ensuring that exposed
employees have 24-hour access to PEP
knowledgeable clinicians, educating staff
about appropriate policies and proce-
dures, and ensuring compliance with
union agreements and applicable depart-
mental, state and federal laws requires a
great deal of planning. The rewards,
however, can be great: creating an envi-
ronment in which employees trust that all
possible measures are in place to protect
them from communicable diseases,
avoiding sanctions from relevant agen-
cies, and most importantly, preventing the
transmission of serious and potentially
fatal BBPs to your colleagues. This article
will address some of the key features of a
correctional BBP PEP program.
• The Law
Each program must ensure that they are
in compliance with applicable federal and
state OSHA regulations. These include
the existence of an exposure control plan
dealing with BBPs including 
1) training of all at-risk employees 
2) provision of free hepatitis B vaccination
to staff (all at-risk employees must either
accept HB vaccination or sign a waiver
form),
3) provision of personal protective equip-
ment and devices, 
4) provision of free post exposure care to
exposed employees, and 
5) maintenance of OSHA logs document-
ing exposures. 
BBP exposure incidents must be regular-
ly evaluated with an eye towards ensur-
ing compliance with BBP policies and,
where possible, modifying procedures to
decrease risk to staff.
• The Risks
In the correctional setting the primary risks
for transmission of hepatitis B (HBV), hep-
atitis C (HCV) and HIV are percutaneous
or mucosal exposure to blood or other
potentially infectious body fluids.
Significant exposures to correctional staff
can occur in the course of providing
healthcare, contact with sharps while
cleaning or searching cells, during physi-
cal altercations, and by intentional
"gassing" in which staff members are
deliberately exposed to a patient's body
fluids. A rough estimation of the risk fol-
lowing one percutaneous exposure to
infectious material is 1/20 for HBV (1/3 if
HB e Ag +), 1/33 for HCV, and 1/333 for
HIV. The risk of HIV transmission follow-
ing a mucous membrane exposure is
estimated to be 1/1100.
Given the nationwide high prevalence of
BBP, in corrections, prevention must be
Occupational Exposure
To Blood Borne Pathogens: 
Post Exposure Prophylaxis (PEP) For Correctional Employees
HEPP News, a forum for correctional
problem solving, evolved out of ongoing dis-
cussions among HIV specialists based at
the Brown University AIDS Program about
the need for HIV updates designed for prac-
titioners in the correctional setting. The
board of editors includes national and
regional correctional professionals, selected
on the basis of their experience with HIV
care in the correctional environment and
their familiarity with current HIV treatment.
HEPP News targets correctional administra-
tors and HIV/AIDS care providers including
physicians, nurses, outreach workers and
case managers. Published monthly and dis-
tributed by fax, HEPP News provides up-to-
the-moment information on HIV treatment,
efficient approaches to administering such
treatments in the correctional environment,
national and international news related to
HIV in prisons and jails, and correctional
trends that impact HIV treatment. Continuing
Medical Education credits are provided by
the Brown University Office of Continuing
Medical Education to physicians who accu-
rately respond to the questions on the last
page of the newsletter; please see last page
for details.
The editorial board and contributors to
HEPP News are well aware of the critical
role prisons and jails play in the treatment
and prevention of HIV. The goal of HEPP
News is to provide reports of effective and
cost-conscious HIV care that can truly be
implemented within the correctional environ-
ment. We hope this newsletter achieves that
goal.
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Letter From the Guest Editor:
This issue of HEPP Newsletter focuses on Post-Exposure Prophylaxis (PEP) in the prison setting.  The lead article, by Dr. Bick, dis-
cusses occupational PEP. What should be done if a correctional officer suffers a deep needle stick injury from a needle found dur-
ing a cell search? This question raises many difficult issues. The article demonstrates how important it is to be prepared, to create
an environment in which, as Bick says, "employees trust that all possible measures are in place to protect them from communica-
ble diseases." It describes how to evaluate the exposure incident, the source, and the exposed individual, and provides information
about how to determine the need for PEP after an occupational exposure.  Dr. Mayer touches upon a more controversial issue:
non-occupational PEP. Interest in non-occupational PEP and its utilization has increased in past years, but many questions remain
unanswered: Who should be given access to this yet unproven prevention strategy? While many have argued that victims of sex-
ual assault should, others suggest that PEP should be available to all who engage in high-risk behavior. The immediate follow-up
question is: would this lead to increased willingness to take risks? And what about providing inmates who engage in forbidden activ-
ity, such as sex and/or injection drug use, with access to PEP if they fear having been exposed to HIV? 
Finally, there is an even more controversial issue: providing access to pre- rather than post-exposure prophylaxis. Prison systems
in most countries have long offered inmates access to condoms. Sexual activity remains forbidden, but everyone knows that it nev-
ertheless happens and carries a high risk of transmission of HIV and other infections. Providing condoms to prisoners to reduce
that risk is a pragmatic public health measure now widely accepted in most countries. Some countries have even started providing
inmates with access to sterile injection equipment. The rationale is the same: injection drug use remains forbidden and cannot be
condoned.  It does, nevertheless, happen, and does so with severe risks of infections further spreading among inmates and their
families. Where access to injection equipment has been provided, this has not lead to increased drug use in prison, has significantly
reduced transmission of HIV and hepatitis B and C, has not created any risk to the security of staff and has been well accepted by
inmates, the staff, and the prison administration -- even after often vehement initial opposition. 
After reading the February edition of HEPP News, you should be able to: Identify procedures for providing PEP following a high-
risk injury including guidelines for management of PEP issued by the U.S. Public Health Service and federal OSHA regulations; dis-
cuss the specific differences between a high and low risk injury requiring PEP; identify complications associated with non-occupa-
tional PEP and discuss the protocol for possible blood borne pathogen exposure to staff.
In closing, one should consider the roles to be taken in efforts to overcome institutional resistance to efficient yet controversial pre-
ventative care, and thus better prevent the spread of HIV and other blood borne pathogens.
Sincerely,
Ralf Jürgens, LL.M., Dr.jur.
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We have invited Ralf Jürgens, JD to be guest editor of this month's issue of HEPP News.  Jürgens is Executive Director of the Canadian HIV/AIDS Legal
Network, a member of the Canadian Ministerial Council on HIV/AIDS, and was coordinator of the Canadian Expert Committee on AIDS in Prisons. He
played a pivotal role in the implementation of condom and sterile injection equipment distribution in the Canadian correctional system. We are all aware
that there is a little (if not a lot) of hesitation on this side of the Canadian border regarding "pre"-exposure prophylactic measures. However, a variety of
uncontrolled events such as drug use, sexual contact, and violence do sometimes occur in correctional settings. We the HEPP News editors, felt it would
be worthwhile to address these topics in the context of this issue on Post-Exposure Prophylaxis. Bear with us and rest assured, we will be addressing
more mainstream topics, such as Tuberculosis, in the next issue. For more information about the Canadian HIV/AIDS Legal Network and pre-exposure
prophylaxis in the correctional setting, visit the network's website at www.aidslaw.ca. We thank Mr. Jürgens for joining us as guest editor for this issue,
and we remind our readers that we welcome feedback.
the cornerstone of an exposure control
plan and will go a long way toward
decreasing those late afternoon calls.
For HBV, an aggressive vaccination
program for at-risk employees is essen-
tial. HBV is the #1 infectious cause of
cancer worldwide (hepatoma), and
more healthcare workers die each year
from complications of occupationally
acquired HBV than the total number
who have acquired HIV on the job in the
entire history of the epidemic. If possi-
ble, obtain HBV serology on all incom-
ing employees, as this data will greatly
simplify future PEP evaluations.
• The Tough Stuff
No, it's not the science, nor the treat-
ment algorithms described below. In the
c rrectional setting, the main difficulty is
creating a mechanism for delivering
PEP to employees within the recom-
mended time frames (1-2 hours in the
case of HIV). Is the closest emergency
r om 3 hours away? Do you have
physicians on site 24-hours per day?
Each facility and system will need to
address these questions individually,
based upon the available resources and
any applicable union agreements. For
those facilities with 24-hour physician
availability, the fastest approach is to
provide HIV PEP, HBIG, and HBV vac-
cine on site. For HIV PEP, following an
initial dose, employees will also need 2-
3 days worth of medications and a pre-
scription to be filled later for a full four
w eks. Keep in mind that not all phar-
macies stock these medications, and
for maximal effectiveness no doses can
be missed. 
A mechanism for obtaining baseline
and follow-up labwork as well as moni-
toring for side effects of PEP must be in
place. If the decision is made to utilize a
nearby emergency room, the initial
wound care and information collection
should rapidly take place at your facility.
P otocols must be in place with the
receiving ER to triage these cases as
emergencies, to provide initial and fol-
low-up doses of PEP, and to arrange
follow-up appointments with Occupa-
tional Health clinics.
Occupational Exposure To Blood Borne Pathogens
continued from page 1
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Is the source material blood, bloody fluid, other potentially 
infectious material (OPIM),† or an instrument contaminated 
with one of these substances?
No PEP needed
Volume No PEP Needed
Yes
OPIM§ Blood or Bodily fluid
No
Mucous membrane or
skin, integrity 
compromised¶
Small
(e.g.m few
drops, short
duration)
Large
(e.g., several drops, major
blood splash and/or longer
duration [i.e., several min-
utes or more])
Less Severe
(e.g., solid needle,
superficial scratch)
More Severe
(e.g., large-bone hollow
needle, deep puncture,
visible blood on device or
needle used in source
patient’s artery or vein)††
Percutaneous 
exposure
Intact skin
only**
Severity
EC 1 EC 2 EC 2 EC 3
What type of exposure has occurred?
*This algorithm is intended to guide initial decisions about PEP and should be used in
conjunction with other guidance provided in this report.
†Semen or vaginal secretions; cerebrospinal, synovial, pleural, peritoneal, pericardial, or
amniotic fluids; or tissue.
§Exposures to OPIM must be evaluated on a case-by-case basis. In general, these body
substances are considered a low risk for transmission in health-care settings. Any unpro-
tected contact to concentrated HIV in a research laboratory or production facility is con-
sidered an occupational exposure that requires clinical evaluation to determine the need
for PEP.
¶Skin integrity is considered compromised if there is evidence of chapped skin, der-
matitis, abrasion, or open wound.
**Contact with intact skin is not normally considered a risk for HIV transmission.
However, if the exposure was to blood, and the circumstance suggests a higher volume
exposure (e.g., an extensive area of skin was exposed or there was prolonged contact
with blood), the risk for HIV transmission should be considered.
††The combination of these severity factors (e.g., large-bore hollow needle and deep
puncture) contribute to an elevated risk for transmission if the source person is HIV-pos-
itive.
STEP 1: Determine the Exposure Code (EC)
STEP 3: Determine the PEP Recommendation
What is the HIVstatus of the exposure source?
HIV negative§§
No PEP needed
Lower titer exposure
(e.g., asymptomatic and 
high CD4 count ***)
Lower titer exposure
(e.g., asymptomatic and 
high CD4 count ***)
HIV SC UnknownHIV SC 2HIV SC 1
HIV positive¶¶ Status 
unknown
Source
unknown
1 1 PEP may not be warranted. Exposure type does not pose a known
risk for HIV transmission. Whether the risk for drug toxicity outweighs
the benefit of PEP should be decided by the exposed HCW and treat-
ing clinician.
1 2 Consider basic regimen.††† Exposure type poses a negligible risk for
HIV transmission. A high HIV titer in the source may justify considera-
tion of PEP. Whether the risk for drug toxicity outweighs the benefit of
PEP should be decided by the exposed HCW and treating clinician.
2 1 Recommend basic regimen.Most HIV exposures are in this category;
no increased risk for HIV transmission has been observed but use of
PEP is appropriate.
2 2 Recommend expanded regimen.§§§ Exposure type represents an
increased HIV transmission risk.
3 2 or 1 Recommend expanded regimen. Exposure type represents an
increased HIV transmission risk.
Unknown If the source or, in the case of an unknown source, the setting where
the exposure occurred suggests a possible risk for HIV exposure and
the EC is 2 or 3, consider PEP basic regimen.
†††Basic regimen is four weeks of zidovudine, 600 mg per day in two or three divided
doses, andlamivudine, 150 mg twice daily.
§§§Expanded regimen is the basic regimen plus eitherindinavir, 800 mg every 8 hours, o
nelfinavir, 750 mg three times a day.
STEP 2: Determine the HIV Status Code (HIV SC)
EC HIV SC PEP  recommendation
§§A source is considered negative for HIVinfection if there is laboratory documentation of a
negative HIVantibody, HIV polymerase chain reaction (PCR), or HIV p24 antigen test result
form a specimen collected at or near the time of exposure and there is no clinical evidence
of recent retroviral-like illness.
¶¶A source is considered infected with HIV (HIV positive) if there has been a positive labo-
ratory result for HIV antibody, HIV PCR, or HIV p24 antigen or physician-diagnosed AIDS.
***Examples are used as surrogates to estimate the HIV titer in an exposure source for pur-
poses of considering PEP regimens and do not reflect all clinical situations that may be
observed. Although a high HIV titer (HIV SC 2) in an exposure source has been associated
with an increased risk for transmission, the possibility of transmission from a source with a
low HIV titer also must be considered.
• Management of Exposures
STEP 1: Wash the site.The initial management of all BBP
exposure is the same: immediately wash with soap and water
all wounds and skin sites that have been in contact with blood
or body fluids. For mucous membranes, flush copiously with
water or saline.
STEP 2: Evaluate the type of exposure.Ask yourself: Did
it involve tissue or fluids capable of BBP transmission? If not,
no further treatment is necessary. If yes, evaluate the
exposed body site. Was the site intact skin, hair, or clothing?
If so, no further treatment is needed. If, however, the poten-
tially infectious material made contact with an infectable body
site (non-intact skin, mucous membrane like the mouth or
eyes, or was parenteral, such as a needle stick or bite), trans-
mission of a BBP is possible.
STEP 3: Evaluate for other source factors.Is the source
known? If the source is notknown, in a correctional setting it
is prudent to proceed as if the source is infected with HIV,
HBV, and HCV. If the source is known, review the source's
chart for HIV, HBV, and HCV serology. Recent negative serol-
ogy and a lack of evidence of high-risk behaviors since the
negative test make the presence of BBPs much less likely. 
In the absence of recent negative serology, proceed as if the
source is infected and initiate whatever measures are allow-
able within your system to obtain stat HIV, HCV and HBV test-
ing of the source.  For those facilities that do not do labwork
on site, it is imperative to have a contract that allows for 24-
48 hour reporting in stat situations.
STEP 4: Evaluate the exposed individual.Is the exposed
person already infected with HBV, HCV, or HIV? Has the indi-
vidual been vaccinated for HBV? If so, was an antibody
response documented?
STEP 5:  HIV PEP (see algorithms)
HIV RISKS: 
The risk for transmission of HIV is increased in cases of deep
injuries.  Those with large gauge hollow bore needles, those
involving devices visibly contaminated with the patient's blood
or used directly in the source's artery or vein, and exposure
to blood with a high titer of HIV (as in late stage AIDS) are
examples.  Among healthcare workers with documented
seroconversions, over 80% experienced a syndrome consis-
tent with primary HIV infection median of 25 days after expo-
sure. Of those who seroconverted, 95% did so within 6
months. 
WHY PEP?:
The evidence for efficacy of PEP comes from both animal
studies with SIV and ACTG 076, which demonstrated that
AZT decreased the transmission of HIV to the offspring of HIV
infected pregnant women. A retrospective analysis of
exposed healthcare workers demonstrated a 81% reduction
in HIV transmission among those given AZT. The recommen-
dations for expanded regimens are extrapolated from what is
known from trials for treatment of established HIV infection.
WHICH PEP?:
Once the evaluations of the exposure incident, the source,
and the exposed individual have taken place as described
above, proceed to the following algorithms 1-3 included in this
article.
Employees with occupational exposure to BBPs require fol-
low-up counseling, post exposure testing, and medical evalu-
ation regardless of whether they receive PEP. Monitoring of
medication toxicities and the management of side effects
must be performed.
STEP 6: Hepatitis B PEP (see HEPPigram)
STEP 7: Hepatitis C
Thus far, there is no effective PEP for the prevention of trans-
mission of HCV. Exposed individuals should have blood
drawn for HCV Ab at baseline, and, if negative, it should be
repeated at 6 weeks, 3 months, and 6 months. If they are
infected, they should be counseled about the possibility of
transmitting HCV to others. Early treatment with Interferon
may be appropriate in some cases if seroconversion occurs.
Not all aspects of BBP PEP are covered in this article.
Issues such as PEP for those exposed to drug resistant
viruses and management of PEP for pregnant workers can
complicate the picture. For an excellent recent reference,
the reader is referred the Public Health Service Guidelines
for PEP published in the MMWR vol. 47/No.RR-7 from May
15, 1998.
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HEPPigram . . . Algorithm for HBV treatment after exposure
HEPPigram: A feature of HEPPNews providing concise solutions to correctional HIV-related problems
If exposed inmate is: And source is:
HBsAg+
And source is:
HBsAg-
And source is:
unknown
Not HBV vaccinated HBIG x1 and
vaccinate
Vaccinate In correctional
settings, treat as if
source were HBsAg+
HBV vaccinated,
unknown response
Test exposure for
HBsAb. If + , no RX. If
– and vaccine booster
No treatment Test exposed for
HBsAB.  If +, no RX. If
- revaccinate
HBV vaccinated,
known non
responder
HBIG x 2 or HBIG x 1
and revaccinate
No treatment In correctional
settings, treat as if
source were HBsAg+
HBV vaccinated,
known responder
No treatment* No treatment* No treatment*
(*see how much easier it is when all of your staff are vaccinated?) adapted from MMWR vol. 46/No. RR-18, December 26, 1997
* Joseph Bick, M.D., Consultant: Agouron, Bristol-Meyers Squibb; Speaker's Bureau: Agouron, Bristol-Meyers Squibb.
A s k  T h e  E x p e r t s  .  .  .
W h a t  W o u l d  Y o u  D o ?
Expert #1
Anne Spaulding, M.D.*
Medical Director
RI Department of Corrections
The RI DOC Health Services has had a protocol for responding to
potential bloodborne pathogen exposure of staff and inmates since
1996. I'll treat the nurse using our guidelines…
1. After cleaning the site with soap and water, I evaluate the nature
and severity of the exposure. A needle stick from a patient likely to
be HIV positive represents a high-risk exposure.  I ask the inmate
patient for permission to evaluate him for HIV/HBV/HCV.
2. After counseling the nurse about the exposure’s significance, I
encourage HIV/HBV/HCV testing (at an outside facility to maintain
confidentiality) to document baseline seronegative status, for work-
man's compensation, in the rare event of seroconversion. I encour-
age repeat testing at 6 weeks, 3 and 6 months postexposure. She
should report any symptom of seroconversion to her outside
provider. Until she has HIV infection ruled out, I recommend that she
use barrier methods during sex and refrain from blood donation.
3. During initial evaluation, I give the first dose of HIV prophylaxis.
In every facility, we maintain emergency packets of
AZT/3TC/Indinivir. She takes this first dose in my presence.  I refer
her for further management to an outside facility to maintain confi-
dentiality at her work site.
Our guidelines take a "one size fits all" approach.  AZT, 3TC, and
Indinavir may not represent the best HIV prophylaxis.  The sexual
partner of the source patient could transmit a virus resistant to her
AZT/3TC. 
Tolerance of Indinavir may be less than Nelfinavir.  However, RI
DOC has made PEP uniform to maximize the number of potential
candidates who take the first dose rapidly.
With the institution of the emergency packet system, health care
workers, correctional officers and inmates have received PEP within
one hour of potential exposure.  Previously, staff went to local hospi-
tals, which sometimes tarried before administering any medication.
During follow-up with an HIV specialist, who will oversee a four-week
regimen of PEP, individualization of further treatment (perhaps D4T
and DDI as reverse transcriptase inhibitors) can occur.  
*No Industry Affiliation
Expert #2
David Alain Wohl, M.D.*
Clinical Assistant Professor, University of North Carolina
HIV Services Co-Director, NC Department of Corrections
The clock is ticking!  The few animal data that actually demon-
strat  any effectiveness of post-exposure prophylaxis (PEP) fol-
lowing retroviral infection indicate that the earlier the administra-
tion of PEP (ideally within 1 hour), the greater the chance of
aborting infection (1).
First Aid, in this case, should consist of simply washing the
wound with soap and water. Use of caustic agents such as
bl ach has no role in cleansing needlestick injuries.
Documentation of the exposure is required by OSHA and is
essential if the health care worker seeks Workman's
C mpensation.  Confidentiality of the HCW and the source
pati nt must be strictly respected.
Ass ss the risk.  The injury in this case was substantial. To the
nurs 's credit, she was wearing gloves, which may have reduced
the amount of blood carried by the needle. The source patient
and HCW must be tested as described in Joe Bick's article (See
page 1). This HCW should be tested for pregnancy. Pregnancy
status may influence her decision regarding initiation of PEP.
The lack of detectable HIV RNA by PCR in the plasma of the
source patient does not rule out HIV infection, but probably
lessens the risk of HIV transmission. It should be assumed the
patient is HIV infected. 
PEP should be offered if the results of the source patient's HIV
status are unavailable within a few hours. The USPublic Health
Service guidelines recommend that either 2 or 3 agents be
administered based on the severity of the exposure and infec-
tiousness of the source. Many find this abiguous. When offering
PEP I try to provide the best chance of preventing infection with
2 nucleosides and a protease inhibitor.  
Selection of PEP regimen in this case is clouded by the history
of the source patient's partner's use of ZDV and 3TC, but it is
is  to assume resistance to ZDV and 3TC is likely. I would offer
D4T, DDI and nelfinavir (1,250 mg BID). This combination should
be potent and unaffected by cross resistance to ZDV and/or
3TC. Nelfinavir's manageable major side effect of diarrhea
should be considered. DDI must be taken on an empty stomach.
I recommend a single dose of DDI be taken before bed. If DDI is
not tolerated, 3TC could be substituted in its place, recognizing
the concern for resistance and its use with ZDV in treating HIV
infected persons with previous ZDV experience.  
The HCW should be counseled to be alert to signs of acute sero-
conversion and safe sex and should have psycological support
services available.  All HCW receiving PEP should be registered
with the PEPRegistry (888-737-4448).
*David Alain Wohl, M.D.
Speaker Bureau:
Roche, 
Bristol Myers Squibb, 
Glaxo and Roxane
This case is adapted from a true "high risk" needle stick exposure in a correctional setting: A nurse was stuck with a needle after
drawing blood from a "high risk" inmate during intake. The nurse was assisting another nurse with the blood draw because the inmate's
veins were difficult to access. She pulled the tourniquet as the second nurse brought the needle out of the vein. At this time, the 21-
gauge needle tip went through her glove and into a vein on the top of her hand, resulting in a large hematoma. The patient was not
known to be HIV seropositive but had a history of intravenous drug use. He was known to have had a sexual partner who was diag-
nosed with AIDS and was treated with AZT/3TC oral combination therapy. He had shared needles and had unprotected sex with this
partner. When the patient's labs came back, he had an undetectable viral load, his HIV serology and western blot were pending, and
his T cell count was 150.
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Case Follow Up
Immediately following the stick, the nurse washed the area with
soap and water and reported it to her supervisor. The physician
supervisor immediately called the National Clinicians' Post-
Exposure Prophylaxis Hotline in San Francisco (888-448-4911).
She was started on triple therapy, and within 30 minutes had taken
her first doses of DDI, D4T, and Nelfinavir. The prison pharmacy
issued medications for the next 2 days and central pharmacy
overnighted the amount needed for the 28 days. She now says:
"DDI was awful but I finally managed to dissolve it in H2O in order
to get it down. I took all of the medications at the times suggested
and finished all 28 days. I had slight side effects, the worst being
severe bouts of diarrhea, but I was able to take another pill for that."
Her HIV and Hep C tests were initially negative (taken at 6 weeks).
We will give you an update on her situation in next month’s issue.
By Kenneth H. Mayer, MD*
Chief, Infectious Disease Division
Memorial Hospital of Rhode Island
Director, Brown University AIDSProgram
On a global basis, more than ¾ of all
new HIV infections are
due to sexual trans-
mission, which is more
than 8,000 every day.
Although a random-
ized, controlled study
of antiretroviral drug
use after a high-risk
exposure appears to be impossible for
logistical and ethical reasons, interest
in this adjunctive means of HIV preven-
tion has been growing. 
The rationale for PEP is based on ani-
mal model data, the efficacy of meth-
ods about other viral infections (e.g.
hepatitis A with immunoglobulin), and
the use of antiretroviral therapy in pre-
venting perinatal HIV transmission.
Also, the results of a CDC retrospective
case-control study suggested that
health care workers who took some
AZT after an occupational exposure
were one fifth as likely to become HIV-
infected as those who did not use med-
ication.  Despite the prohibition of sex-
ual activity in correctional facilities, the
occurrence of HIV exposure due to
sexual contact makes PEP a relevant
topic for correctional health care.
• Questions Raised
More than 2 years ago, I received my
first call from an emergency room ask-
ing me how to manage a survivor of a
sexual assault whose assailant was an
IDU, hence judged to be at increased
risk for HIV. This encounter raised
many questions that are still useful
today, which include: 
1. Who should receive non-occupation-
al PEP?
2. How certain do providers need to be
that the source of exposure is HIV (+)
or at increased risk?
3. What are appropriate regimens?
4. For how long should it be adminis-
tered?
5. Will the assumption that PEP is
available and efficacious result in
increased HIV risk taking behavior?
The answers to these and other impor-
tant questions remain unclear, but over
the past few years, the interest in non-
occupational PEP and its utilization
have definitely increased. However,
many providers have been concerned
that knowledge of the existence of a
"morning after" pill, or a "chemical con-
dom" would result in
increased risk taking
behavior among high
risk HIV (-) people.
Also, the CDC/US
Public Health Service
(MMWR, September
25, 1998) recommen-
dations that regimens of multiple anti-
retrovirals be used for a month's dura-
tion, plus the lack of significant publici-
ty about PEP, may be responsible for
the relatively small number of people
utilizing this yet unproven prevention
strategy.
• Fenway's Experience
Over the past year, at the Fenway
Community Health Center where more
than 1,000 HIV (+) men and women
receive primary care in Boston, we
have tracked the utilization of non-
occupational PEP and have had the fol-
lowing observations:
1. PEP utilization is, albeit slowly,
increasing from one or
fewer calls per week
to more than one a
week.
2. Most of the expo-
sures involve high-risk
activities, e.g. unpro-
tected anal or vaginal
intercourse, but only about 1/3 of the
exposures were with partners known to
be HIV infected. Of almost 50 requests
for PEP, almost 30% were due to lower
risk exposures (e.g. semen in the eye
with a partner of unknown serostatus).
3. The vast majority of people who
receive PEP (usually AZT+3TC
+Indinavir or Nelfinavir) reported side
effects (usually nausea, myalgias,
fatigue, insomnia, diarrhea) but were
able to complete a one-month regimen.
4. The majority of participants come
back for follow-up at 3 and 7 months,
and there have been no new infections
thus far.
5. Much of the cost of this expensive
intervention was due to the need for on-
going supportive counseling services
for the men and women who presented
for PEP, including triage because of
domestic trauma, sexual assault, +/-
on-going substance use. Despite this
triage, almost 10% of the cohort pre-
sented for a repeat course of  PEP
within one year.
• Messages
The "take home" messages from the
Fenway Community Health Center and
that of other programs like the San
Francisco Health Department, regard-
ing non-occupational PEP are:
1.There is a growing awareness among
men and women engaging in high-risk
behavior that PEP may help prevent an
exposure from resulting in an infection.
The Fenway did not advertise its pro-
gram, so contacts with the center were
via provider triage or word of mouth. 
2. The need for these programs will
grow over time until we have an effec-
tive vaccine and/or microbicide.
3. Many of the persons who access
PEP will need to be referred to compe-
t nt mental health professionals,
because:
a. They have sustained a traumatic
experience, e.g. sexual assault.
b. They are overly anxious, and do not
need PEP, but
rather need to deal
with their guilt about
what they perceive
so risky.
c. They are likely to
use PEP as an
excuse to avoid
modifying recurrent risk-taking behav-
iors.
In the correctional setting, other ques-
tions will emerge such as the feasibility
of prompt access, the ability to maintain
confidentiality, and the net effect on risk
taking behavior among incarcerated
individuals. These need to be
assessed. While it is unlikely that the
efficacy of non-occupational PEP will
ever be able to be studied in a con-
trolled environment, it seems likely that
its utilization will grow as part of the
increasing array of responses to pre-
vent HIV transmission.
*Kenneth H. Mayer, M.D.,
Grant Research/Support:
Triangel, Roche, Immune Response Corp.
Speaker’s Bureau:
Agouron, Bristol Myers Squibb, Glaxo Wellcome
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Non-Occupational Post-Exposure Prophylaxis (PEP)
Despite the prohibition of 
sexual activity in correctional
facilities, the occurrence of 
HIV exposure due to sexual 
contact makes PEP a 
relevant topic for correctional 
health care.
Many providers have been 
concerned that knowledge of 
the existence of a "morning after"
pill, or a "chemical condom" 
would result in increased risk 
taking behavior among high risk 
HIV (-) people.
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AIDS Pathogenesis Meeting
Keystone, CO
January 7-13, 1999
…was the bucolic setting for the HIV Vaccine Development:
Opportunities and Challenges  and AIDS Pathogenesis meet-
ings from January 7-13, 1999. 
Five hundred scientists and researchers attending the joint
symposia heard the keynote address given by Dr. Robert
Gallo, Institute of Human Virology, University of Maryland.
Gallo hit the highlights of AIDS research performed or pub-
lished in the past year, noting the work of Wayne Hendrickson
and Joe Sodroski, who determined the crystal structure of the
HIV-1 protein gp 120 complexed with a fragment of human
CD4. Gallo summarized the dynamic cellular interaction that
occurs during the entry of human immunodeficiency virus
(HIV) into CD4+ T cells. He speculated that drugs that inter-
fered with one of the three key components of viral entry
(gp120, CD4, and the chemokine receptor) would have a sig-
nificant impact on the control of HIV disease in the near future.
Expanding on this theme, Dr. Peter Kim of the Whitehead
Institute, Cambridge, MA, presented his model of viral entry.
Binding of HIV-1 gp120 to CD4 of the target cell membrane
results in a quick molecular rearrangement that facilitates sub-
sequent binding of gp120 to the appropriate chemokine recep-
tor. It is clear that understanding of the mechanisms of HIV
entry into cells is useful in employing strategies for blocking
viral infection at a cellular level.  One such strategy developed
by Jack Nunberg, et al from Montana Biotechnology Center,
University of Montana, proposes that the conformational
changes which occur during binding and fusion may expose
"critical targets," that are not otherwise available to the
immune system, to prime antibodies capable of neutralizing
the virus. Nunberg showed that anti sera raised against these
targets are active against many different HIV-1 strains. These
new findings suggest that the virus may have an "Achilles
heel" vulnerable to attack by preventive and therapeutic vac-
cines.
In other news, Doug Nixon of the Aaron Diamond AIDS
Research Center in New York City described the relationship
between broad immune responses to HIV and control of infec-
tion. He reported on 12 patients who were given extremely
early (within 120 days of HIV infection) Highly Active
Antiretroviral Therapy (HAART). This relatively small clinical
trial suggested that extremely early initiation of HAART may
disarm the natural immune response to HIV by limiting the
immune system's exposure to the virus. In this study, patients
who had broad immune responses to HIV (as measured using
the new tetramer assay) appeared to have better control of
their HIV infection. Dr. Nixon concluded that broad immune
responses appeared to be related to better control of HIV
infection, that early initiation of HAART may limit the amount
of immune system training that appears to occur during the
early phase of HIV infection, and he suggested that post-
HAART therapeutic vaccination may be one "safe" way to
broaden the immune system's repertoire of weapons against
HIV. These hypotheses are under study.
During one of the final talks of the meeting, Neal Nathanson,
the new Director of the Office of AIDS Research, emphasized
the broad theme of the conference by stating that a broad
understanding of HIV immunopathogenesis was required to
develop the "broad" range of weapons we will need to combat
HIV infection and disease. He warned researchers against
adopting a "holy grail" approach to the search for new treat-
ments and vaccines. He suggested that we keep in mind that
we may need multiple barriers to HIV infection and to prevent
dev lopment of disease. He was extremely optimistic about
the prospects for HIV vaccine development, stating that
prospects for the development of a polio vaccine, in the
1940's, were equally bleak as the prospects for developing an
AIDS vaccine appear to be at present. 
While most speakers agreed with the keynote speakers at the
joint Vaccines and Immunopathogenisis meetings that combi-
nation antiretroviral therapies have led to major advances in
the clinical care of AIDS patients, many speakers stated that
adherence, availability, resistance, and cost are still major
obstacles in HIV treatment.  There was consensus among this
gro p that the desired approach was to further integrate the
lat st knowledge about HIV pathogenesis into vaccine devel-
opment with the ultimate objective to prevent or control HIV
infection through immunologic intervention.
c ntributed by Judy George and Anne DeGroot
ACA Winter Conference
Nashville, TN
January 16-21, 1999
The American Correctional Association held its annual
Winter Conference January 16-21, 1999 at the Opryland
Hotel and Conference Center in Nashville, where Newton
Kendig, M.D., Chief of Infectious Disease for the Federal
Bureau of Prisons and John Miles, Special Projects
Manager for Corrections and Substance Abuse Activities at
th  Centers for Disease Control, spoke on managing infec-
tious disease.
Kendig discussed exposure risks for HIV, Hepatitis B and
Tuberculosis among corrections officers and other staff and
recommended post-exposure prophylaxis in high-risk sce-
narios and precautions, such as barrier protection. 
Miles discussed the correlation between substance abuse
and infectious disease among inmates and, in particular,
described the need to view disease management in prisons
as a public health duty.  He recommended collaborations
with public entities and community organizations to help
direc  inmates to treatment once they are released from
prison and pre-release and discharge planning in facilities.  
c ntributed by Michelle Gaseau
AIDS Pathogenesis Meeting. . . . January 7-13, 1999
ACA Winter Conference. . . . January 16-21, 1999
F e b r u a r y  1 9 9 9  •  V o l u m e  2 ,  I s s u e  2 8
FAX HEPP NEWS BACK AT 800.671.1754 FOR ANY OF THE FOLLOWING: (please print clearly or type)
____  Yes, I would like to update/correct (circle one) my contact information.
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1999 National Conference on African-Americans and AIDS
February 25-26, 1999
Sponsored by:Rollins School of Public Health of Emory
University, the Johns Hopkins medical institutions and the
Institute of Human Virology at the University of Maryland.
Financial support is from Bristol-Myers Squibb.
Renaissance Washington DC Hotel
Contact:Ms. Mary Hess, 
Senior Territory Manager, Bristol-Myers-Squibb Immunology 
tel: 410.995.0599
fax: 410.995.0610
voice mail: 800.492.7016, ext. 1340
Improving the Management of HIV Disease
February 20, 1999  Los Angeles, CA
March 6, 1999  Boston, MA
March 24, 1999  New York, NY
April 21, 1999  Chicago, IL
This course, sponsored by International AIDS Society-USA
(IASUSA), reviews the most recent development in the field of
HIV disease pathogenesis and antiretroviral management.
Expert faculty will speak on timely and clinically relevant issues
in the management of HIV disease.
Contact:IASUSA
1001 B O'Reilly Ave
PO Box 29916
San Francisco, CA 94129-0916
tel:  415.561.6720
fax: 415. 561.6740
e-mail:  info@iasusa.org
website: www.iasusa.org
HIV in Prisons Conference
Thursday, February 25, 1999 - from 9:00am to 4:00pm.
One of a series of conferences targeted to service providers in
New York.  Topics include HIV therapies in prison and in dis-
charge planning, the former inmate and barriers to HIV treat-
ment, and policy considerations.  Speakers will be Harry
Schuman, MD, medical director at Rikers,  Steven Nesselroth
from Osborne, and Liz Mastroieni from AIDS Counseling and
Education at Bedford Hills Correctional Facility.
Contact:Carlos Arboleda
fax:  212.367.1528
American Correctional Health Services Association 1999
Training Conference
March 11-14, 1999
Sheraton Gateway
Atlanta, GA
Contact: ACHSA 
PO Box 10
Glenn Dale, MD 20769 
website: www.corrections.com/achsa
11th National HIV/AIDS Update Conference: 
Partnering Science and Practice 
March 23-26, 1999
Sponsored by:AmFar (www.nauc.org)
Bill Graham Civic Auditorium
San Francisco, CA
Contact: KREBS Convention Management Services
tel: 415.920.7000
fax: 415.920.7001
e-mail: krebsconv@aol.com
website: www.citysearch.com/sfo/krebs
1999 Community Planning Leadership 
Summit for HIV Prevention
March 24-27, 1999
Sponsored by:AED, CDC, NASTAD, NMAC
Pittsburgh Hilton & Towers, Pittsburgh PA
Contact:Harry Williams at NMAC
tel: 202.483.6622 
fax: 202.483.1127
Bureau of Justice Assistance (BJA): 
National Partnership Meeting
April 6-8, 1999 Washington DC
Contact:National Criminal Justice Association
444 N. Capitol Street, Suite 618
Washington, DC 20001
tel: 202.624.1440
website: http://www.sso.org/ncja
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through April
15, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. The first step in the initial management of a potential HIV
exposure is to:
A) administer an initial start dose of medication
B) evaluate the serostatus of the exposed individual
C) wash contact sites with water and either soap or 
saline, depending on site
D) administer HBV vaccine booster
E) do not treat  
2a. Each year, more deaths result from HIV acquired on the
job than from complications of occupationally acquired HBV. 
TRUE or FALSE?
2b. The risk of transmission following a percutaneous expo-
sure to HCV is estimated to be roughly 100 times that of a
percutaneous exposure to HIV. 
TRUE or FALSE? 
3. The risk for transmission of HIV is increased in cases
involving the following:
A) deep injuries
B) injuries with large, gauge, hollow, bore needles
C) injuries caused by devices visibly contaminated with 
the patient's blood or used directly in the source's 
artery or vein
D) exposure to blood with a high titer of HIV (as in late 
stage AIDS).
E) all of the above
4. Federal and state OSHA regulations require that correc-
tional BBS exposure control programs include which of the
following:
A) training of all at risk employees
B) provision of free Hepatitis B vaccination to staff 
C) provision of personal protective equipment and 
devices
D) provision of free post exposure care
E) documentation of exposures
F) regular evaluation for compliance
G) all of the above
5. Of almost 50 requests for PEP over the past year at the
Fenway Community Health Center, approximately how
many were due to lower risk exposures?
A) 50
B) 30
C) 25
D) 15
E) 0
6. For which of the following components of PEP protocol
did Dr. Spaulding and Dr. Wohl describe different respons-
es?
A) evaluation of HBV
B) drug regimen
C) follow-up HIV testing at 6 months
D) an initial start dose at 1 hour
BROWN UNIVERSITY SCHOOL OF MEDICINE • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2  • PROVIDENCE RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) sponsor continuing
medical education activities for physicians.  Each physician should claim only those hours of credit that he/she actually spent in the educational activi-
ty.  This activity has been planned and implemented in accordance with the Essentials and Standards of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommendations
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the Brown
University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
case study 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
save the date 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
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